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ABSTRACT
Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and
Pagets disease of the bone. To date, a number of BPs-namely alendronate, risedronate, and
minodronate-have been launched to market. Nitrogen-BPs (N-BPs) act by inhibiting the enzyme
farnesyl pyrophosphate synthase (FPPS), and several crystal structures of complexes between FPPS
and N-BPs have been identified. Understanding the physical basis of the binding between proteins
and small molecules is an important goal in both medicinal chemistry and structural biology. Here,
we conducted density functional theory calculations for BPs and their surrounding residues and
were able to successfully reproduce experimental results qualitatively. In addition, we found that
both the side chain and backbone of Phe 99 are important for binding between minodronate and
FPPS, suggesting that the strong activity of minodronate comes from its interaction with Phe 99,
which alendronate and risedronate lack.
1. Introduction
Bisphosphonates (BPs) are the most widely used and ef-
fective treatment for osteoporosis and Pagets disease of the
bone [1], and a number of BPs have been launched to mar-
ket. All BPs contain a phosphate-carbon-phosphate (P-C-
P) backbone structure and can be classfied into two groups:
non-nitrogen-containing BPs (non-N-BPs) and nitrogen-
containing BPs (N-BPs), which are further divided into two
additional groups (alkyl-amino BPs and heterocyclic N-
BPs) [2],. N-BPs act by inhibiting farnesyl pyrophosphate
synthase (FPPS), which is a key enzyme in the mevalonate
pathway (Fig. 1) [3]. Farnesyl pyrophosphate synthetase
(FPS; EC 2.5.1.10) produces the 15-carbon farnesyl py-
rophosphate which is utilized in the synthesis of sterols,
dolichols, carotenoids, coenzyme Q, heme a, and farnesy-
lated proteins. Several crystal structures of human FPPS
complexed with N-BPs have been published. In a pre-
vious study, we conducted an interaction energy analysis
using the fragment molecular orbital (FMO) method [4].
Our findings indicated that the following interactions may
be important in the potency of N-BPs: hydrogen bonding
with Thr 201 and/or Lys 200, where a bifurcated bond is
more potent than a single bond; CH-O hydrogen bonding
with the backbone carbonyl oxygen atom of Phe 99; and -
interaction with the sidechain of Phe 99. Truhlars group
recently developed the global hybrid meta functionals M05-
2X [5] and M06-2X [6] and demonstrated that these meth-
ods can be effectively applied to many problematic systems
[7, 8]. Here, we conducted quatum mechanical calculations
for several BPs (minodronate, risedronate, alendronate)
and their surrounding residues using the M06-2X method.
2. Methods
To construct our model, three-dimensional coordinates
of the FPPS/BP complex were obtained from Protein Data
Bank (2F92 for alendronate [9], 1YV5 for risedronate [10],
and 3B7L for minodronate [11]). Both side chains of the
BPs and surrounding amino acid residues (within 4.5 A˚of
the side chain of minodronate) were cut from the crystal
structures, including the BP, Phe 99, Leu 100, Asp 103,
Thr 167, Gln 171, Lys 200, Thr 201, Tyr 204, and Gln 240
(Fig. 1). For Lys 200 and Asp 103, uncharged protonation
was used. Addition and energy minimization of hydro-
gen atoms was conducted using MOE 2008.1001 (Chem-
ical Computing Group, Inc., Quebec, Canada), a model
classified as wild. To examine the effect of Phe 99 on the
interaction between FPPS and BP, Phe 99 was removed
from the wild system, in a model known as delF99. To
examine the side chain of Phe 99, Phe 99 was substituted
for alanine, and energy minimization of the side chain was
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conducted, in a model known as F99A. The Gaussian 09
program was used for the ab initio molecular orbital cal-
culations. Energy was calculated using M06-2X/6-31G*
[6]. Each interaction enery value was calculated using the
following equation:
Gbind = E(BP + AA, v) − E(BP,w) − E(AA, v) (1)
where Gbind is the binding energy, E(BP+AA,v) the en-
ergy of BP and amino acids complex it in vacuo, E(BP,w)
the energy of BP in water, and E(AA,v) the energy of
amino acids in vacuo.
Fig. 1. Side chain of minodronate and surrounding
residues
3. Results and Discussion
Binding energy values calculated using M06-2X/6-31G*
are summarized in Table 1. The binding energy of min-
odronate was the smallest among the three bisphosphates
tested (-3.9 kcal/mol), while that of alendronate was the
largest (7.9 kcal/mol). These results are consistent with
previously obtained experimental data [12]. For minodronate,
the binding energy of F99A was larger than that of the wild
system by 2.3 kcal/mol, indicating that the side chain of
F99 has a significant interaction with minodronate. Fur-
ther, the binding energy of dF99 was larger than that of
F99A by 5.3 kcal/mol, indicating that the backbone of F99
also has a significant interaction with minodronate, due to
the CH-O hydrogen bond between the backbone of F99 and
minodronate. For risedronate, the binding energy of dF99
was larger than that of the wild system by 3.1 kcal/mol,
indicating that F99 has a moderate interaction with rise-
dronate. Further, the binding energy of dF99 was almost
the as same as that of F99A, indicating that the sidechain
of F99 has little interaction with risedronate. For alen-
dronate, the binding energy of dF99 is almost the as same
as that of the wild system, indicating that F99 does not
have a significant interaction with alendronate. In con-
trast, with HF/6-31G*, the respective binding energies of
minodronate, risedronate, and alendronate were 26.5, 11.8,
and 16.1 kcal/mol, showing that the binding energy of min-
odronate is quite larger than that of alendronate. This un-
derestimation of the binding energy of minodronate may be
due to the fact that HF calculations cannot accurately es-
timate CH-O hydrogen bonding and π-π interactions, two
major driving forces of binding between BP and FPPS as
determined in our previous study [4].
Table 1. Binding energy between BPs and surrounding
residues
name energy (kcal/mol)
wild F99A dF99
alendronate 7.9 8.3 9.5
risedronate -3.3 -2.9 -0.2
minodronate -3.9 -1.6 3.7
Here, we described preliminary findings regarding inter-
action between bisphosphates and their surrounding residues.
Our calculations qualitatively reproduced previous experi-
mental findings and indicated that both the side chain and
backbone of Phe 99 are important for binding between min-
odronate and FPPS. The characteristics of three BPs (min-
odronate, risedronate, and alendronate) are summarized in
Table 2. All three BPs have a hydrogen bond with Thr 201,
and both minodronate and risedronate have a hydrogen
bond with Lys 200. The CH-O hydrogen bond with Phe
99, however, is a unique feature of minodronate, and thus
the strong binding of minodronate to FPPS is determined
to be due to these three hydrogen bonds, termed a triple
hydrogen bond. Minodronate is a third generation BP orig-
inally developed at Astellas Pharma which was approved
and launched in 2009 in Japan as an oral treatment for
osteoprosis. Minodronate was synthesized by a team lead
by one of the authors (M. Takeuchi) and has been shown
to have 100- to 1000-fold stronger bone resorption activ-
ity than pamidronate [13]. Although minodronate shows
the strongest activity among BPs, the reason for its strong
activity remains unclear. As described in the Introduc-
tion, our previous calculations using the FMO method in-
dicated that hydrogen bonding with Thr 201 and/or Lys
200, CH-O hydrogen bonding with the backbone of Phe
99, and π-π interactions with the sidechain of Phe 99 are
all important for binding between minodronate and FPPS
[4]. The results obtained in the present study support the
above hypothesis.
Further work is underway to improve the calculation.
• The coordinates for quantum mechanical calculation
will be optimized using M06-2X.
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Table 2. Features of interaction among BPs
name H bond
Phe 99 Lys 200 Thr 201
alendronate not exist not exist exist
risedronate not exist exist exist
minodronate exist exist exist
Fig. 2. Comparision of three BPs
• Larger basis sets (such as 6-311+G(d,p)) will be used
for quantum mechanical calculations.
• The basis set surperposition error (BSSE) will be es-
timated using the counterpoise method [14, 15].
• The effect of protonation states will be considered.
4. Conclusion
Results of M06/02X calculations for several BPs and
their surrounding residues Showed that Phe 99 in FPPS
is important for binding between minodronate and FPPS.
The M06/02X calculation is a promising tool for providing
deeper insight into interaction between drugs and recep-
tors.
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